Pfizer’s Prevnar turned in consensus-beating sales of $1.53 billion—up 7% over the same period last year—thanks to government purchases internationally and in the U.S. More: Pfizer's Prevnar posts .53B in Q4 sales, handily beating consensus Source: fierce
read moreAn API maker in Bizen, Japan, has joined a growing list of Japanese drugmakers to be criticized by the FDA in warning letters. In this case, the agency was concerned enough to also ban the company’s products from the U.S.
read moreOn Pfizer’s fourth-quarter conference call, Morgan Stanley analyst David Risinger congratulated company executives on their “efforts to educate Washington having finally paid off.” And the way CEO Ian Read sees it, those congratulations are well deserved. More: Pfizer pats itself
read moreBiogen has found itself the target of an age discrimination lawsuit that hinges on whether the company marginalized a former manufacturing executive as part of a campaign to cater to millennials. More: Age bias suit against Biogen claims its NC
read moreEli Lilly’s portfolio is in the middle of a big shift, with newer diabetes drugs taking the reins of that franchise and its blockbuster erectile dysfunction drug Cialis, already suffering from copycat Viagra competition, on its way to a generics
read moreAt least £140 million is expected to be released into the NHS over the next five years because of price discounts negotiated via the Cancer Drugs Fund. More: CDF to save NHS £140m over five years Source: News
read more© 1994 - 2023 B.M. Pharmaceuticals